4.7 Review

Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder

Journal

CNS NEUROSCIENCE & THERAPEUTICS
Volume 18, Issue 6, Pages 441-451

Publisher

WILEY
DOI: 10.1111/j.1755-5949.2012.00318.x

Keywords

Combined cognitive-behavioral and pharmacological treatment; Dopamine and the reward system; Emotional temperament; Major depressive disorder

Funding

  1. Abbott Laboratories
  2. Alkermes
  3. Lichtwer Pharma GmbH
  4. Lorex Pharmaceuticals
  5. Aspect Medical Systems
  6. Astra-Zeneca
  7. Bristol-Myers Squibb Company
  8. Cephalon
  9. Cyberonics
  10. Eli Lilly Company
  11. Forest Pharmaceuticals Inc.
  12. GlaxoSmithkline
  13. J & J Pharmaceuticals
  14. Novartis
  15. Organon Inc.
  16. PamLab, LLC
  17. Pfizer Inc
  18. Pharmavite
  19. Roche
  20. Sanofi/Synthelabo
  21. Solvay Pharmaceuticals, Inc.
  22. Wyeth-Ayerst Laboratories
  23. Belvoir Publishing
  24. Abbot Laboratasuories
  25. Alkermes, Inc.
  26. AstraZeneca
  27. BioResearch
  28. BrainCells Inc.
  29. Bristol-Myers Squibb
  30. CeNeRx BioPharma
  31. Clinical Trials Solutions, LLC
  32. Clintara, LLC
  33. Covance
  34. Covidien
  35. Eli Lilly and Company
  36. EnVivo Pharmaceuticals, Inc.
  37. Euthymics Bioscience, Inc.
  38. Forest Pharmaceuticals, Inc.
  39. Ganeden Biotech, Inc.
  40. Icon Clinical Research
  41. i3 Innovus/Ingenix
  42. Johnson & Johnson Pharmaceutical Research Development
  43. National Alliance for Research on Schizophrenia & Depression (NARSAD)
  44. National Center for Complementary and Alternative Medicine (NCCAM)
  45. National Institute of Drug Abuse (NIDA)
  46. National Institute of Mental Health (NIMH)
  47. Novartis AG
  48. Organon Pharmaceuticals
  49. PamLab, LLC.
  50. Pfizer Inc.
  51. Pharmavite(R) LLC
  52. Photothera
  53. Roche Pharmaceuticals
  54. RCT Logic, LLC
  55. Sanofi-Aventis US LLC
  56. Shire
  57. Synthelabo

Ask authors/readers for more resources

Background: Given the limited efficacy of current pharmacotherapy for major depressive disorder (MDD) and the historical decline in antidepressant development, there is increasing clinical urgency to develop more effective treatments. Objectives: To synthesize findings from clinical psychology and affective neuroscience related to the construct of emotional temperament; to examine the effects of antidepressants on the temperament dimensions of positive (PA) and negative affectivity (NA); and to propose a biobehavioral research paradigm for the treatment of MDD. Methods: We begin with an introduction to PA and NA, which emphasizes their construct development, historical context, and relevance to psychopathology. We then review studies of antidepressant effects on PA and NA, and explore two related hypotheses: (1) Cause-correction: The antidepressant response may fundamentally occur through changes in emotional temperament, with subsequent spread to syndrome or symptom changes; (2) preferential effects: Antidepressants with different mechanisms of action may have preferential effects on PA or NA. Results: Preliminary findings appear to support the cause-correction hypothesis; there is insufficient clinical evidence to support the preferential effects hypothesis. Conclusions: PA and NA are biologically based temperament dimensions, which modulate emotional, motivational, and behavioral responses to positive and negative incentives. They can be altered by antidepressants, and may independently contribute to depression improvement. In addition, the distinct biobehavioral features of PA and NA suggest that combined pharmacological and cognitivebehavioral treatments targeting these dimensions may have specific, and perhaps, synergistic antidepressant effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available